Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) will present initial clinical and preclinical data for zovegalisib (RLY-2608) in vascular anomalies at the ISSVA World Congress 2026 in Philadelphia, May 19-22, 2026.
The company expects to report clinical data on approximately 20 efficacy-evaluable patients in a Late Breaking Abstract on May 20, 2026, and will present preclinical murine-model results showing lesion regression with minimal hyperinsulinemia on May 22, 2026. Presentations will be posted on the company website at session start times.
AI-generated analysis. Not financial advice.
Positive
- Initial clinical dataset of ~20 efficacy-evaluable patients
- Preclinical murine data showing lesion regression
- Preclinical report of minimal hyperinsulinemia in models
Negative
- Clinical data limited to approximately 20 patients, small sample
- No efficacy or safety numeric readouts disclosed in the announcement
News Market Reaction – RLAY
On the day this news was published, RLAY declined 0.72%, reflecting a mild negative market reaction. Argus tracked a peak move of +16.2% during that session. Our momentum scanner triggered 86 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $17M from the company's valuation, bringing the market cap to $2.33B at that time. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RLAY gained 8.24% while close peers were mixed: AVBP +3.64%, TNGX +1.05%, IMTX +0.50%, NRIX -0.58%, VIR -0.88%, indicating a stock-specific reaction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Breast cancer data | Positive | -1.0% | Phase 1/2 ReDiscover data for zovegalisib plus fulvestrant at Phase 3 dose. |
| Jun 05 | Trial collaboration | Positive | -0.9% | Collaboration with Pfizer on triplet therapy including RLY-2608 and fulvestrant. |
Recent clinical trial announcements for zovegalisib have coincided with small negative price moves despite seemingly constructive updates.
This announcement on initial zovegalisib data in vascular anomalies follows prior clinical updates focused on PI3Kα‑mutated HR+/HER2‑ metastatic breast cancer and a collaboration trial. On Mar 16, 2026, Phase 1/2 ReDiscover data at the Phase 3 dose showed median PFS of 11.1 months and 43% ORR, yet shares fell modestly. Earlier, a Jun 5, 2024 collaboration with Pfizer on a triplet regimen also saw a slight decline, suggesting past clinical news did not produce strong positive reactions.
Historical Comparison
In the past, RLAY’s clinical trial updates (2 events) averaged a -0.96% move. Today’s +8.24% reaction to new zovegalisib vascular anomalies data timing represents a notably stronger response than prior clinical news.
Clinical development has progressed from breast cancer-focused trials and a triplet collaboration toward expanding zovegalisib into PIK3CA-driven vascular anomalies, adding a genetic disease indication alongside oncology.
Market Pulse Summary
This announcement highlights upcoming initial clinical and preclinical data for zovegalisib in PIK3CA-driven vascular anomalies, with about 20 efficacy-evaluable patients expected. It extends a program already active in metastatic breast cancer into vascular malformations. Historically, clinical trial news for zovegalisib has produced modest share moves. Investors may watch the ISSVA 2026 presentations, overall cash runway, and ongoing Phase 3 breast cancer development to assess how this new indication fits into Relay’s broader strategy.
Key Terms
pi3kα medical
pik3ca-driven vascular malformations medical
vascular anomalies medical
hyperinsulinemia medical
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients.
Late Breaking Clinical Abstract:
Abstract Title: Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3Kα Inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations
Abstract Number: 488
Session: Late Breaking Abstract Session
Date/Time: Wednesday, May 20, 4:30 p.m. ET
Preclinical Abstract:
Abstract Title: Zovegalisib (RLY-2608), a Novel, Mutant-selective, PI3Kα Inhibitor, Induces Lesion Regression, with Minimal Hyperinsulinemia, in Murine Models of PIK3CA-mutant Vascular Malformations
Abstract Number: 404
Session: Session 9 - Combined
Date/Time: Friday, May 22, 11:10 a.m. ET
The presentations will be available at the start of the sessions on the company’s website at https://relaytx.com/publications/.
About Zovegalisib
Zovegalisib is the lead program in Relay Therapeutics’ efforts to discover and develop mutant-selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers and all vascular anomalies. Zovegalisib has the potential, if approved, to address a significant portion of the approximately 140,000 patients with HR+/HER2- breast cancer with a PI3Kα mutation and the estimated 170,000 patients with vascular anomalies driven by a PI3Kα mutation per year in the United States, one of the largest patient populations for a precision medicine.
Traditionally, the development of PI3Kα inhibitors has focused on the active, or orthosteric, site. The therapeutic index of orthosteric inhibitors is limited by the lack of clinically meaningful selectivity for mutant versus wild-type (WT) PI3Kα and off-isoform activity. Toxicity related to inhibition of WT PI3Kα and other PI3K isoforms results in sub-optimal inhibition of mutant PI3Kα with reductions in dose intensity and frequent discontinuation. The Dynamo® platform enabled the discovery of zovegalisib, the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome these limitations. Relay Therapeutics solved the full-length cryo-EM structure of PI3Kα, performed computational long time-scale molecular dynamic simulations to elucidate conformational differences between WT and mutant PI3Kα, and leveraged these insights to support the design of zovegalisib. Zovegalisib is currently being evaluated in multiple metastatic breast cancer studies and a Phase 1/2 study designed to treat patients with PIK3CA (PI3Kα) mutation driven vascular anomalies. For more information on zovegalisib, please visit here.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics’ strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics’ portfolio; the timing of clinical data readouts for zovegalisib; the expected therapeutic benefits and potential efficacy and tolerability of zovegalisib, both as a monotherapy and in combination with other agents, and its other programs; the clinical data for zovegalisib; the interactions with regulatory authorities and any related approvals; and the potential commercialization and market opportunity for zovegalisib. The words “may,” “might,” “will,” “could,” “would,” “should,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade or regulatory developments, such as tariffs, beyond Relay Therapeutics’ control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics’ drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
